French Travelers' Knowledge of Risk of Acquiring ESBL-PE (MDR bacteria)

November 9, 2017 updated by: CHU de Reims

Poor Knowledge Among French Travelers of the Risk of Acquiring Multidrug-resistant Bacteria During Travel

Since it is not routine practice in France to raise public awareness about the risk of acquiring multidrug resistant Enterobacteriaceae (MRE) during international travel, the investigators aimed to determine, among French travelers attending a consultation for travel medicine, patients level of knowledge about the risk of acquiring MRE.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Since it is not routine practice in France to raise public awareness about the risk of acquiring multidrug resistant Enterobacteriaceae (MRE) during international travel, The investigators aimed to assess, among persons attending a consultation for travel medicine and international vaccines, patients level of knowledge regarding the risk of acquiring MRE, preventive behaviours and the need to inform health professionals that they had recently travelled if the patients require medical care after their return. A cross-sectional study was performed in the consultation for travel medicine and international vaccination in Reims University Hospital, France. All adult travellers who attended this consultation between January 2016 and May 2016 and who completed the questionnaire were included in the study. The questionnaire was completed before the planned travel. The travellers answered the questionnaires before seeing the physician.

Study Type

Observational

Enrollment (Actual)

191

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Reims, France
        • Damien JOLLY

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital between January 2016 and May 2016 and who completed the questionnaire were included in the study.

Description

Inclusion Criteria:

  • Adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital
  • Adult who completed the questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Travel medicine
All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
Other: Questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Level of knowledge regarding multidrug resistant Enterobacteriaceae
Time Frame: Day 1
The questionnaire was completed before the planned travel and recorded information on the patient's knowledge of the definition of multidrug resistant bacteria (MDR), knowledge of the factors associated with acquiring MDR bacteria, consumption of antibiotics during previous travel, awareness of the need to inform health professionals about the recent trip in case of health problems after return, perceived need for more information about MDR bacteria, desired source of such information. The questions about knowledge were designed to be as simple as possible, with closed answers ('yes', 'no', 'don't know')
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CHU de Reims

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2016

Primary Completion (ACTUAL)

May 1, 2016

Study Completion (ACTUAL)

June 1, 2016

Study Registration Dates

First Submitted

November 8, 2017

First Submitted That Met QC Criteria

November 9, 2017

First Posted (ACTUAL)

November 13, 2017

Study Record Updates

Last Update Posted (ACTUAL)

November 13, 2017

Last Update Submitted That Met QC Criteria

November 9, 2017

Last Verified

November 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2016Ao006

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Travel Medicine

Clinical Trials on Questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe